PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 26 filers reported holding PHARVARIS N V in Q4 2022. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89,003,705 | +37.8% | 4,264,672 | 0.0% | 25.24% | +8.0% |
| Q2 2023 | $64,567,134 | +251.8% | 4,264,672 | +87.2% | 23.37% | +129.7% |
| Q1 2023 | $18,353,922 | -29.0% | 2,278,575 | -0.8% | 10.17% | +27.0% |
| Q4 2022 | $25,837,988 | +46.7% | 2,296,710 | 0.0% | 8.01% | +96.5% |
| Q3 2022 | $17,616,000 | -65.4% | 2,296,710 | -0.2% | 4.08% | -71.9% |
| Q2 2022 | $50,862,000 | +21.8% | 2,301,451 | -0.1% | 14.48% | +56.4% |
| Q1 2022 | $41,771,000 | +26.0% | 2,303,310 | 0.0% | 9.26% | +55.1% |
| Q4 2021 | $33,145,000 | -18.8% | 2,303,310 | 0.0% | 5.97% | +46.8% |
| Q3 2021 | $40,838,000 | -4.8% | 2,303,310 | 0.0% | 4.07% | -19.7% |
| Q2 2021 | $42,911,000 | -33.4% | 2,303,310 | 0.0% | 5.06% | -17.3% |
| Q1 2021 | $64,447,000 | – | 2,303,310 | – | 6.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $57,834,000 | 8.52% |
| venBio Partners LLC | 2,303,310 | $40,838,000 | 4.07% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $56,392,000 | 3.50% |
| Foresite Capital Management V, LLC | 364,142 | $6,456,000 | 2.01% |
| VR Adviser, LLC | 552,882 | $9,803,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,608,471 | $28,518,000 | 0.56% |
| Cormorant Asset Management, LP | 689,731 | $12,229,000 | 0.50% |
| Novo Holdings A/S | 418,943 | $7,428,000 | 0.38% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $42,909,000 | 0.25% |
| DAFNA Capital Management LLC | 35,074 | $622,000 | 0.16% |